Afamelanotide: how Scenesse helps people live with light sensitivity

For someone with erythropoietic protoporphyria, or EPP, daylight can mean pain rather than freedom. Even a short spell outside may bring on severe burning sensations. Afamelanotide was developed to make that daily constraint less restrictive: it encourages the skin to produce more of its protective pigment and can increase the time people with EPP spend in light without pain.

The medicine is sold as Scenesse, an implant placed beneath the skin by a healthcare professional. Its history began with research into tanning, but its established medical use is much more specific. The evidence discussed here concerns adults with EPP, not cosmetic tanning products or general protection against sun damage. 1

At a glance

Question	What to know
What is it?	A synthetic, longer-lasting analogue of alpha-melanocyte-stimulating hormone, or α-MSH.
How does it work?	It activates the melanocortin-1 receptor, MC1R, and increases production of eumelanin.
What is its medical use?	Increasing pain-free light exposure in adults with EPP.
How is it given?	As the Scenesse implant, administered by a healthcare professional.
What is its approval history?	The archived sources describe EU approval in 2014 and US approval in 2019.
What needs monitoring?	Adverse effects, changes in pigmentation and existing moles; the cited label calls for twice-yearly full-body skin examinations.

What is afamelanotide?

Afamelanotide is a peptide designed to imitate α-MSH, a hormone involved in skin pigmentation. Changes to the natural molecule make the analogue more stable and longer-lasting. Research literature also uses the names NDP-MSH and Melanotan I. Clinuvel Pharmaceuticals developed the medicine marketed as Scenesse. 1

The formulation matters. Scenesse is a small, dissolvable implant that releases the drug over several days. It is placed under the skin by a healthcare provider; this is not a daily self-injection regimen. A product sold online under a similar peptide name should not be assumed to have the same formulation, quality or clinical evidence.

From tanning research to a treatment for EPP

In the 1980s, University of Arizona researchers Mac Hadley and Victor Hruby investigated whether a synthetic version of α-MSH could produce pigmentation without sun exposure. Their starting idea was that a protective tan might reduce skin-cancer risk. That was a research rationale, not proof that afamelanotide prevents skin cancer. Natural α-MSH broke down too quickly for the intended use, prompting work on a more stable analogue. 2

That programme produced two related compounds. The linear peptide Melanotan I became afamelanotide. The cyclic Melanotan II followed a separate development path, including work that led to a different drug for sexual dysfunction. The shared history does not make the compounds or their uses interchangeable.

The focus gradually moved from tanning to medical protection for people with severe light sensitivity. The sources record European approval for EPP in 2014 and US approval in 2019. The archive also describes warnings about unapproved injectable products marketed online as Melanotan I or II. These products are distinct from the regulated implant.

How does it work?

Afamelanotide activates MC1R on melanocytes, the cells that make pigment. This signal increases eumelanin, the darker form of melanin. Eumelanin absorbs and scatters light and can help neutralise reactive oxygen species generated by light exposure. The drug stimulates that pathway through a receptor, rather than requiring the ultraviolet exposure normally associated with tanning. 1

In EPP, the relevant problem involves a build-up of protoporphyrin IX. When this molecule interacts with visible light, it can generate reactive oxygen species that damage tissue and produce intense pain. More eumelanin helps reduce the light reaching and interacting within the skin. The intended benefit is a longer interval of light exposure before pain occurs.

This mechanism explains why pigmentation is relevant to EPP, but it should not be stretched into a promise of complete protection from sunlight. More pigment is not a reason to disregard sun protection or changes in the skin. The implant’s gradual release is also part of the treatment studied; evidence for that formulation cannot simply be transferred to other preparations.

What did the clinical trials show?

Two multicentre, randomised, double-blind, placebo-controlled studies reported together in 2015 included 168 adults with EPP. They measured pain-free time in direct sunlight, an outcome closely connected to everyday life with the condition. 3

Study	Participants	Findings reported in the archived source
US pivotal trial	94 adults	Median pain-free direct-sunlight exposure was 69.4 hours with afamelanotide and 40.8 hours with placebo; P = 0.04.
European pivotal trial	74 adults	Median pain-free exposure was 6.0 hours with afamelanotide and 0.8 hours with placebo; P = 0.005. The study reported 77 phototoxic reactions in the treatment group and 146 with placebo.
Dutch observational cohort	117 patients	The archive reports that 98% remained on treatment over a median follow-up of 2.0 years.

The two randomised trials are described in the 2015 publication. The later Dutch results come from an observational cohort. Staying on treatment is useful information about experience in practice, but it is a different outcome from a placebo-controlled comparison of pain-free light exposure.

The trial numbers are accumulated exposure measures, not a guarantee that one person can safely spend that many consecutive hours outside. The figures belong to their respective study settings; the large difference between the US and European totals should not be interpreted as a head-to-head comparison. The archive reports improved quality of life in both trials. Headache, nausea, nasopharyngitis and back pain were among the common adverse events recorded. 3

Is it approved, and what is it prescribed for?

The archived FDA prescribing information describes Scenesse for increasing pain-free light exposure in adults with a history of phototoxic reactions from EPP. The supplied source dates the US approval to October 2019; the EMA record documents its European regulatory history.

The intended benefit is practical: more time in light without the burning pain that can severely restrict daily activity. The source also cites consensus guidance published in 2023 recommending afamelanotide to prevent phototoxic symptoms in EPP. 4

These sources do not establish approval for cosmetic tanning or another condition. The archive calls Scenesse the first US treatment shown to increase pain-free light exposure in EPP and describes it as the only FDA-approved drug stimulating melanin for photoprotection. Those are time-sensitive statements from the supplied source, not a newly checked comparison of all current medicines.

Side effects and skin monitoring

The prescribing information cited by the archive lists implant-site reactions, nausea, throat pain and cough, fatigue, increased pigmentation, darkening of existing moles, dizziness or drowsiness, respiratory tract infection and skin irritation. These effects belong beside the benefits when considering what treatment involves. 1

The source also links to DailyMed prescribing information for postmarketing reports of serious hypersensitivity reactions, including anaphylaxis. The existence of such reports is different from knowing how frequently the reaction occurs.

Because pigmentation and existing moles may darken, the cited label recommends full-body skin examinations twice a year. Monitoring is part of the treatment, not an optional detail to leave out of a discussion about its effect on skin colour.

Common questions

Is afamelanotide the same as Melanotan I?

Melanotan I is a research name associated with afamelanotide. That naming connection does not make an online tanning product equivalent to the studied Scenesse implant. The formulation and the regulated product matter.

Can it be used simply to get a tan?

The approved use described in the supplied sources is EPP in adults. Cosmetic tanning is not the indication discussed here, and the EPP trials do not establish a benefit-risk balance for that use.

Does it cure EPP or make sunlight harmless?

The benefit described is an increase in pain-free light exposure. That is not the same claim as curing the underlying disorder or removing every consequence of sunlight. Skin monitoring and appropriate light protection remain relevant.

How is it administered?

A healthcare professional places a dissolvable Scenesse implant beneath the skin. It releases afamelanotide gradually over days. This article does not provide an injection or dosing protocol.

The source archive connects this topic with Melanotan I and Melanotan II. Their related names are a reason to distinguish the compounds and products carefully, not to borrow one product’s evidence for another.

Additional library links retained from the original article: Bacitracin, Dalbavancin / Oritavancin / Telavancin, Daptomycin, Difelikefalin, Ecallantide and Icatibant. These are navigation links, not evidence that the medicines have the same effects.

The pivotal trial publication is Langendonk and colleagues, 2015: DOI 10.1056/NEJMoa1411481. Its PubMed entry, the Dutch cohort, consensus guidance, FDA label, DailyMed label, EMA record, development history and approval news are retained for source review.

Editorial note: This local draft is an original adaptation of the archived Superpower guide, reused with permission provided by the user. It retains the source’s evidence and limitations but has not undergone independent clinical or source-to-claim review. The original site’s reviewer credit does not apply to this adaptation. This is educational information, not individual medical advice.